BIOCON.NS Profit & Loss
Biocon Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 8 years on file
(FY2018-19 to FY2025-26)
· fetched 2026-08-23 21:39
| Line item | FY2018-19 | FY2019-20 | FY2020-21 | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹55.14 Bn | ₹63.67 Bn | ₹71.06 Bn | ₹81.84 Bn | ₹111.74 Bn | ₹147.56 Bn | ₹152.62 Bn | ₹169.27 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | ₹60.29 Bn | ₹63.67 Bn | ₹71.06 Bn | ₹81.84 Bn | ₹111.74 Bn | ₹147.56 Bn | ₹152.62 Bn | ₹169.27 Bn | SegmentRevenueFromOperations |
| Other Income | ₹1.44 Bn | ₹1.61 Bn | ₹2.54 Bn | ₹2.13 Bn | ₹3.76 Bn | ₹8.65 Bn | ₹12.08 Bn | ₹3.42 Bn | OtherIncome |
| Total Income | ₹56.59 Bn | ₹65.29 Bn | ₹73.60 Bn | ₹83.97 Bn | ₹115.50 Bn | ₹156.21 Bn | ₹164.70 Bn | ₹172.69 Bn | Income |
| Cost of Materials Consumed | ₹19.80 Bn | ₹21.68 Bn | ₹24.30 Bn | ₹28.14 Bn | ₹31.91 Bn | ₹50.72 Bn | ₹42.77 Bn | ₹52.78 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹1.27 Bn | ₹0.85 Bn | ₹0.68 Bn | ₹1.61 Bn | ₹6.26 Bn | ₹6.83 Bn | ₹6.27 Bn | ₹13.63 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-2.10 Bn | ₹-2.01 Bn | ₹-2.90 Bn | ₹-2.57 Bn | ₹-1.54 Bn | ₹-8.57 Bn | ₹2.94 Bn | ₹-9.49 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹11.65 Bn | ₹14.59 Bn | ₹17.41 Bn | ₹18.80 Bn | ₹21.81 Bn | ₹26.64 Bn | ₹31.44 Bn | ₹35.08 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹0.71 Bn | ₹0.65 Bn | ₹0.58 Bn | ₹0.68 Bn | ₹4.19 Bn | ₹9.74 Bn | ₹8.97 Bn | ₹9.90 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹4.48 Bn | ₹5.52 Bn | ₹7.15 Bn | ₹8.14 Bn | ₹11.13 Bn | ₹15.69 Bn | ₹16.87 Bn | ₹19.57 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹10.59 Bn | ₹12.53 Bn | ₹15.04 Bn | ₹16.15 Bn | ₹28.18 Bn | ₹38.95 Bn | ₹37.53 Bn | ₹42.73 Bn | OtherExpenses |
| Total Expenses | ₹46.39 Bn | ₹53.81 Bn | ₹62.26 Bn | ₹70.96 Bn | ₹101.95 Bn | ₹140.00 Bn | ₹146.80 Bn | ₹164.19 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹10.19 Bn | ₹11.47 Bn | ₹11.34 Bn | ₹13.01 Bn | ₹13.55 Bn | ₹16.21 Bn | ₹17.90 Bn | ₹8.51 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹1.95 Bn | ₹0.68 Bn | ₹0.13 Bn | ₹-1.11 Bn | ₹-2.91 Bn | ₹-0.12 Bn | ₹0.96 Bn | ₹-4.03 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹12.14 Bn | ₹12.15 Bn | ₹11.47 Bn | ₹11.90 Bn | ₹10.64 Bn | ₹16.09 Bn | ₹18.87 Bn | ₹4.48 Bn | ProfitBeforeTax |
| Tax Expense | ₹2.12 Bn | ₹3.15 Bn | ₹2.21 Bn | ₹2.12 Bn | ₹2.54 Bn | ₹2.27 Bn | ₹4.57 Bn | ₹0.79 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹10.03 Bn | ₹8.71 Bn | ₹8.46 Bn | ₹7.72 Bn | ₹6.43 Bn | ₹12.98 Bn | ₹14.29 Bn | ₹3.69 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹9.05 Bn | ₹7.48 Bn | ₹7.41 Bn | ₹6.48 Bn | ₹4.63 Bn | ₹10.22 Bn | ₹10.13 Bn | ₹3.86 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹15.30 | ₹6.32 | ₹6.24 | ₹5.44 | ₹3.88 | ₹8.55 | ₹8.46 | ₹2.82 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹15.20 | ₹6.30 | ₹6.19 | ₹5.42 | ₹3.87 | ₹8.54 | ₹8.46 | ₹2.82 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from BIOCON.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).